Two new rule changes in Canada approved by College of Physicians and Surgeons of Ontario (CPSO) will stop a General Practitioner from advertising as a cosmetic surgeon so that people may be able to undergo cosmetic surgery with a trained professional. The practice of family doctors performing liposuctions and breast enlargements without proper training has been increasing in Canada.

 Photo by Shazron

Clinical studies have found that certain types of bacteria residing in the gut of babies with a family history of allergic conditions can reduce the number of young ones who go on to develop eczema. Eczema currently affects about 10% of all infants, half of whom go on to develop other allergic conditions, such as hayfever or asthma. The studies presented at the International Symposium offer hope that babies’ natural defenses can be boosted with the use of the right bacterial strains and appropriate prebiotic mixtures and the that the risk of their developing eczema can be reduced.

 Photo by Kekka

Toronto Cosmetic Clinic has introduced the StarLux® 500 Laser and Pulsed Light Platform service to expand its treatment products for the aesthetic improvement and health of the body’s largest organ, the skin. The revolutionary new device performs Acne Treatment, Non-Ablative Laser Skin Resurfacing, Laser Skin Tightening and both pigmented and vascular Lesion Removal. The StarLux® 500, manufactured by Palomar Medical Technologies Inc, has the ability to perform Laser Hair Removal and Photorejuvenation as well.

VeraFil saline implants have been approved by the FDA for soft tissue reconstruction around the eye. This technology has been used for years in Europe and South America as permanent lip augmentation, under the name FulFil. The VeraFil implant is made from highly biocompatible materials, with a long track record of safety in the human body, and is designed to remain flexible.

Provectus Pharmaceuticals Inc has received allowance of its patent application in the European Union for its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance for another patent application in Canada, covering applicator devices used with PH-10 and related agents. PH-10 is currently undergoing phase 2 clinical testing in New York City for the treatment of moderate to severe psoriasis, and Provectus expects to commence phase 2 testing for another indication within the next few months.

According to a research conducted by a team led by Dr. Stilianos E Kountakis, a specific protein profile present in the blood of patients suffering from chronic sinusitis may enable physicians to objectively diagnose and treat the disease. The study published in the March/April issue of the American Journal of Rhinology used surface enhanced laser desorption ionization time-of-flight mass spectroscopy to assess protein expression in the blood. The research depicted that chronic sinusitis patients had a profile that was missing in 38 healthy people.